Experimental Post Doctoral Fellow

A position is now available for a highly motivated Postdoctoral Fellow to join the research group of Ana Cvejic, Peter Campbell and Open Targets partners at the Wellcome Sanger Institute (WSI).

About Open Targets

 Open Targets aims to provide evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness   of   pharmacological   intervention   on   these   targets, using   genome-scale   experiments   and   analysis.   This   pioneering public-private   partnership   between   Sanofi, Bristol Meyer Squibb, EMBL-EBI, GlaxoSmithKline, and   the   Wellcome   Sanger   Institute,   aims   to provide  a R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community(http://www.opentargets.org).

About the Project/Role: 

The project will combine state-of-the-art single-cell data generation with spatial transcriptomics to study the spatial distribution of diverse immune cells in cancer, and discover putative cell-cell interactions across the tumour microenvironment. It will utilise an array of in vitro tumour assays to examine the role of newly identified genes in tumour growth in non-small cell lung cancer (NSCLC). A particular focus will be on target genes expressed on myeloid cells that facilitate their interactions with tumour cells as well as other immune cells.

This position could be based at the Wellcome Sanger Institute or at the University of Cambridge in Ana Cvejic's lab.

About You:

You will have a PhD with significant experience in molecular and cell biology. Knowledge in the field of immunology, cancer biology and inflammation would be highly advantageous. You will be able to demonstrate critical thinking, passionate about science, and keen to learn and improve skills in a supportive research environment. You will be part of a multidisciplinary team and will be tasked with proactively seeking and maintaining appropriate collaborations. You will also be expected to drive forward the project, working closely with biologists, clinicians and bioinformaticians within and outside the group to accomplish scientific objectives.

Job Logo
Open Targets
Grade
PDF
Salary per annum
32,780 - 41,093
Full Time, Part Time, Flexible Working
Full Time
Contract Type
Fixed Term
Contract Length
2 years
Closing Date
7th December 2021
Job Reference
84543

Essential Skills

Technical Skills:

  • PhD in immunology, cancer biology, biological sciences (or similar)
  • Good publication record 
  • Extensive experience in flow cytometry and cell culture 
  • Experience with CRISPR screening 

Competencies and Behaviours:

  • Team player with the ability to work with others in a collegiate and collaborative environment 
  • Ability to effectively prioritise, multi-task and work independently
  •  Demonstrates inclusivity and respect for all. 
  •  Highly organised

Other information

Please apply with your CV and a cover letter outlining your suitability for the role addressing the criteria set out above and in the job description.

This is a rolling advert, we will consider applications and hold interviews on an ongoing basis so the role may close early if a successful appointment is made.

About Open Targets

Open Targets is a pioneering public-private partnership between European Bioinformatics Institute (EMBL-EBI), GlaxoSmithKline (GSK), the Wellcome Sanger Institute (Sanger), Sanofi and Bristol Meyers Squibb (BMS), located at the Wellcome Genome Campus in Hinxton, near Cambridge, UK.  

Open Targets brings together expertise from five complementary institutions to generate evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. Open Targets aims to provide an R&D framework that applies to all aspects of human disease to improve the success rate of discovering new medicines and share data openly in the interest of accelerating drug discovery.